vemurafenib
Showing 1 - 25 of 94
Melanoma Trial in Tampa (XL888, Vemurafenib)
Active, not recruiting
- Melanoma
- XL888
- Vemurafenib
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Aug 18, 2022
Solid Tumors, Hematologic Cancers, Metastatic Cancers Trial in Paris (Vemurafenib)
Active, not recruiting
- Solid Tumors
- +2 more
- Vemurafenib
-
Paris, FranceTredaniel
May 18, 2022
Melanoma Trial in Ottawa, Toronto, Montreal (Vemurafenib, Cobimetinib)
Active, not recruiting
- Melanoma
- Vemurafenib
- Cobimetinib
-
Ottawa, Ontario, Canada
- +2 more
Oct 25, 2022
Histiocytosis Trial in Warsaw (Vemurafenib)
Recruiting
- Histiocytosis
- Vemurafenib
-
Warsaw, Mazovian, PolandMother and Child Institute
Aug 2, 2022
Thyroid Carcinoma Trial in New York (Vemurafenib, serial 124I PET/CT, thyrotropin alpha)
Active, not recruiting
- Thyroid Carcinoma
- Vemurafenib
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 28, 2022
Melanoma Trial in Napoli (Vemurafenib, Peg-interferon, Cobimetinib)
Completed
- Melanoma
- Vemurafenib
- +2 more
-
Napoli, ItalyFondazione G.Pascale
Feb 23, 2022
Melanoma Trial in Pittsburgh (Pembrolizumab, Vemurafenib, Cobimetinib)
Terminated
- Melanoma
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Cancer Center Hillman Cancer Center
Dec 10, 2021
BRAF NP_004324.2:p.V600X, KRAS wt Allele, Metastatic Malignant Solid Tumor Trial in Houston (biological, drug, other)
Active, not recruiting
- BRAF NP_004324.2:p.V600X
- +6 more
- Cetuximab
- +4 more
-
Houston, TexasM D Anderson Cancer Center
Sep 22, 2022
Melanoma Trial in Louisville (Vemurafenib, Metformin)
Recruiting
- Melanoma
- Vemurafenib
- Metformin
-
Louisville, KentuckyJames Graham Brown Cancer Center-University of Louisville
Oct 22, 2021
Melanoma (Skin), Skin Cancer, Skin Melanoma Trial in Tampa (Vemurafenib, Cobimetinib)
Recruiting
- Melanoma (Skin)
- +3 more
- Vemurafenib
- Cobimetinib
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022
Pancreas Cancer Trial in Scottsdale (Vemurafenib, Sorafenib)
Recruiting
- Pancreas Cancer
- Vemurafenib
- Sorafenib
-
Scottsdale, ArizonaHonorHealth Research Institute
Oct 28, 2021
Solid Tumor, Haematological Malignancy, Melanoma Trial in United Kingdom (Vemurafenib, Cobimetinib)
Recruiting
- Solid Tumor
- +11 more
- Vemurafenib
- Cobimetinib
-
Belfast, United Kingdom
- +16 more
Mar 2, 2023
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas Trial in Canada, United States (Vemurafenib)
Active, not recruiting
- Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
- Vemurafenib
-
Los Angeles, California
- +20 more
Jan 4, 2023
Colorectal Cancer Trial in Shanghai (Vemurafenib, Cetuximab)
Recruiting
- Colorectal Cancer
- Vemurafenib
- Cetuximab
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Aug 15, 2021
CRC Trial in Beijing (HL-085, Vemurafenib)
Not yet recruiting
- CRC
- HL-085
- Vemurafenib
-
Beijing, Beijing, ChinaBeijing Oncology Hospital
Feb 6, 2022
Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular Trial in United States (I-124 PET/CT lesion dosimetry,
Recruiting
- Thyroid Carcinoma
- +5 more
- I-124 PET/CT lesion dosimetry
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Mar 3, 2022
Hairy Cell Leukemia, Leukemia, Leukemia, Hairy Cell Trial in United States (Vemurafenib, Obinutuzumab)
Active, not recruiting
- Hairy Cell Leukemia
- +2 more
- Vemurafenib
- Obinutuzumab
-
New Haven, Connecticut
- +8 more
Feb 7, 2022
Cancer Trial in Melbourne (Trametinib, Cobimetinib, Binimetinib)
Recruiting
- Cancer
- Trametinib
- +14 more
-
Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
Nov 4, 2022
NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)
Recruiting
- Non-small Cell Lung Cancer
- MPDL3280A
- +3 more
-
London, United KingdomUniveristy College London Hospital
Feb 22, 2022
Metastatic or Locally Advanced Malignancies Trial in Germany (Vemurafenib, Cobimetinib, Atezolizumab)
Recruiting
- Metastatic or Locally Advanced Malignancies
- Vemurafenib
- +7 more
-
Berlin, Germany
- +5 more
Jan 2, 2023
Rare Tumor, Refractory Tumor Trial in Shanghai (Gefitinib, Erlotinib, Afatinib)
Recruiting
- Rare Tumor
- Refractory Tumor
- Gefitinib
- +11 more
-
Shanghai, Shanghai, ChinaShanghai Changzheng Hospital
Feb 16, 2022
Targeted Therapies in BRAF Positive Metastatic Melanoma in US
Active, not recruiting
- Melanoma
- Encorafenib
- +5 more
-
New York, New YorkPfizer Investigational Site
Feb 18, 2022